Treatment of Locally Advanced Head and Neck Cancer

Induction Chemotherapy with TPF

The American Society of Clinical Oncology recommends TPF (Taxane, Platinum, 5-Fluorouracil) as a induction regimen for locally advanced head and neck cancers, with demonstrated efficacy in multiple phase III trials 1, 2
The standard TPF regimen consists of docetaxel 60-75 mg/m², cisplatin 60-75 mg/m², and 5-fluorouracil 600-750 mg/m² as continuous infusion for 5 days, administered every 3 weeks, as recommended by the National Comprehensive Cancer Network 1
Guidelines recommend 3 cycles of induction TPF, though a minimum of 2 cycles is considered acceptable, according to the American Society of Clinical Oncology 2, 3
Induction TPF has shown significant improvements in overall survival, progression-free survival, distant failure-free survival, and locoregional failure-free survival compared to concurrent chemoradiation alone, with a high level of evidence 1, 2

The National Comprehensive Cancer Network recommends consolidation with concurrent chemoradiation as the standard approach after induction chemotherapy 2, 4
Weekly cisplatin (40 mg/m²) is an appropriate regimen for the concurrent phase after induction chemotherapy, as recommended by the American Society of Clinical Oncology 4, 5
The cumulative cisplatin dose during the concurrent phase should ideally reach 160-200 mg/m² for optimal efficacy, according to the National Comprehensive Cancer Network 1, 5

Treatment should commence within 21-28 days from the last cycle of induction chemotherapy to minimize the risk of treatment failure, as recommended by the American Society of Clinical Oncology 2, 3
Grade 3-4 toxicities commonly observed with TPF include neutropenia (35%), leukopenia (27%), and diarrhea (8%), with a moderate level of evidence 1
Weekly cisplatin regimens are associated with improved quality of life compared to triweekly schedules, according to the American Society of Clinical Oncology 1

For patients who cannot tolerate cisplatin during concurrent chemoradiation, alternative agents include carboplatin (AUC 5-6), oxaliplatin (70 mg/m² weekly), or nedaplatin (100 mg/m² triweekly), as recommended by the American Society of Clinical Oncology 1, 7
Cetuximab may be considered as an alternative radiosensitizer in patients who cannot tolerate platinum-based chemotherapy, according to the National Comprehensive Cancer Network 4

Regular follow-up with comprehensive head and neck examinations is essential, as recommended by the National Comprehensive Cancer Network 6
Surveillance should include evaluation for locoregional recurrence and distant metastases, with a high level of evidence 6
Long-term monitoring for late toxicities is important, particularly for those who received the full treatment course, according to the National Comprehensive Cancer Network 6